Prevention of pruritus with ethyl-chloride in skin prick test: a double-blind placebo-controlled prospective study by unknown




with ethyl‑chloride in skin prick test:  
a double‑blind placebo‑controlled prospective 
study
Amir Gal‑Oz1,2, Shmuel Kivity2, Yacov Shacham2, Elisheva Fiszer2, Ori Rogowsky3 and Gil Chernin1*
Abstract 
Background: Ethyl‑chloride (EC) spray was recently shown to be an effective antipruritic agent, when given 15 min 
after histamine skin‑prick test (SPT), without changing the wheal and flare reaction. We aimed to investigate the anti‑
pruritic effect of EC on SPT, when given prior to SPT.
Methods: A double‑blind placebo‑controlled prospective study. Overall, 44 volunteers underwent histamine SPT on 
both arms to trigger local pruritus. Prior to test, they were randomly treated with EC spray on one arm and saline spray 
(placebo) on the other. Subjects as well as researchers were blinded to the type of applied sprays. The wheal and flare 
reaction was measured after the SPT and subjects reported the intensity of pruritus following EC/placebo using a 
validated pruritus questionnaire (indexes 1–3) and a visual analog scale (VAS).
Results: Significant improvement in pruritus was reported following treatment with EC compared with placebo for 
all four studied parameters. Index 1 in EC 3.7 ± 2.3 versus 5 ± 3.5 (p = 0.007) in placebo, index 2 in EC 2.6 ± 2.1 versus 
3.8 ± 2.8 (p = 0.002) in placebo, index 3 of EC 6.3 ± 3.8 versus 8.8 ± 5.8 (p = 0.03) and VAS in EC 3.7 ± 1.9 versus 
4.4 ± 2.3 (p = 0.003). There were no significant differences between EC and placebo in terms of the wheal and flare 
indurations area.
Conclusions: Ethyl‑chloride has an effective antipruritic agent, when given before histamine SPT. Its use did not 
change the wheal and flare reaction, making it ideal for prevention of pruritus, secondary to allergy skin test, without 
masking the results.
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Background
Skin prick tests (SPT) for the diagnosis of IgE mediated 
allergy are relatively safe procedures. Nevertheless, it 
may cause severe sensation of either pain or pruritus in 
both children and adults [1, 2]. Therefore, measures to 
prevent or reduce these symptoms may be warranted. 
Topical agents such as eutectic mixture of local anesthet-
ics (EMLA; AstraZeneca LP, Wilmington, DE), have been 
shown to improve symptoms with skin testing, yet these 
agents may mask the wheal and flare response areas, thus 
limiting its usefulness [2–5].
Ethyl-chloride (EC) is an anesthetic agent used in a 
vapo-coolant spray for topical anesthesia in minor sur-
gical procedures, minor sports injuries, pre-injection 
anesthesia and myofascial pain [1, 6]. Scarce data exist 
on the potential effects of topical EC spray on pain and 
pruritus in skin allergy testing and whether its use may 
mask the wheal and flare indurations areas. Apply-
ing topical EC prior to SPT did not significantly reduce 
the pain sensation although a trend toward pain alle-
viation was observed [1]. We have shown that EC spray 
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was effective as an antipruritic agent when given after 
histamine SPT [7]. Topical EC was not associated with 
changes in the wheal and flare reaction [1, 7]. Only few 
case reports of allergic contact dermatitis from EC and a 
positive patch testing with EC were previously published 
[8–10]. Considering its widespread use as a local anes-
thetic, it is probably an uncommon adverse event of EC 
spray.
In the current double-blind placebo-controlled pro-
spective study, we aimed to investigate the antipruritic 
effects of EC-spray, when given prior to the histamine 




A double-blind placebo-controlled prospective study was 
conducted between February 2013 and October 2013. 
The study protocol was approved by the local ethics com-
mittee, and the participants signed an informed consent 
with permission to publish.
Included and excluded subjects
Included were adult volunteers (age >18 years), willing to 
participate in study.
Exclusion criteria: (1) subjects with active skin disease 
or factitious urticaria. (2) Patients treated with analge-
sics, other medications that may affect pain such as (e.g., 
Gabapentin), antihistamines or systemic steroids within 
7 days prior to the experiment. (3) Patients with neuro-
pathic disorders or dermatographism. (4) Subjects with a 
history of oncological disease. (5) Immunocompromised 
patients, not including controlled diabetes mellitus (DM). 
(6) Breastfeeding women. (7) Subjects with active skin 
disease, and (8) subjects with current or recent (<7 days) 
febrile disease.
Study protocol
All subjects underwent the histamine SPT on both arms 
in order to trigger local pruritus, by the same well trained 
physician. Histamine was introduced in increasing con-
centrations on three spots along both forearms: 2.5, 5.0 
and 10.0 mg/ml. Normal saline was used as negative con-
trol on fourth spot. Prior to SPT, The affected areas were 
treated with EC (Gebauer, Cleveland, OH, USA) spray on 
one arm and saline spray (placebo) on the other.
Ethyl-chloride was applied per package recommenda-
tion (i.e. for 3–7 s at a distance of about 15 cm, just until 
the skin began to frost) 5 s before initiation of histamine 
SPT. Placebo spray was applied for the same time and at 
the same distance on the other arm using a sprayer that 
mimicked the EC-spray. Subjects as well as research-
ers were blinded to the sprays used. The wheal and flare 
reactions were measured by the same researcher (A.G.O.) 
15  min following SPT. The borders of the indurations 
area were marked and copied to a clear tape. Then the 
wheal area was measured (in mm2). Subjects rated pru-
ritus by using a visual analog scale (VAS) and a pruritus 
questionnaire (see below), 15  min following the hista-
mine SPT.
Pruritus questionnaire
Despite the clinical importance, there is no validated 
questionnaire for the evaluation of pruritus. The ques-
tionnaire we used was based on a pruritus questionnaire 
previously validated in uremic patients by Yosipovitch 
et al. [7, 11]. We used only part of the referenced ques-
tionnaire which is relevant for the evaluation of the sense 
of itching—the verbal descriptor scale of itch sensation 
and ‘the severity of pruritus’. It included three indexes. 
In index 1, subjects were asked to rank the severity of 
six pruritus sensations (‘tickling’, ‘stinging’, ‘crawling like 
ants’, ‘stabbing’, ‘pinching’ and ‘burning’) on a scale from 
0 (=none) to 3 (=severe), and these ranks were summed. 
Hence, the index 1 final score ranged between 0 and 
18. In index 2, subjects were asked to rank the severity 
of four pruritus dimensions (‘bothersome’, ‘annoying’, 
‘unbearable’ and ‘worrisome’) on a scale from 0 (=none) 
to 3 (=severe), and these ranks were summed. Hence, 
the index 2 final score ranged between 0 and 12. Index 3 
included the sum of both prior indexes. Hence, it ranged 
between 0 and 30.
Visual analog scale
The VAS is usually used to evaluate pain intensity. In this 
study it was used to evaluate pruritus intensity. It con-
sisted of a 10-cm line anchored at one end by the label 
‘no itch’ and at the opposite end by the label ‘very strong 
itch, as bad as could possibly be’. Pruritus was ranked 
from 1 (no pruritus) to 10 (maximal pruritus).
Statistical analysis
Continuous variables were expressed as means and 
standard deviation. The one-way Kolmogorov–Smirnov 
test was used to assess the distributions of parametric 
variables. The Paired t test was used to compare mean 
VAS scores and mean pruritus indexes between the arms 
treated with EC and arms treated with placebo. A p value 
of less than 0.05 was considered statistically significant 
(two sided). Version 21.0 of the SPSS statistical package 
(SSPS Inc., Chicago, IL, USA) was used to perform all the 
statistical evaluations.
Results
Forty-four healthy volunteers (males = 19; females = 25) 
underwent histamine-SPT.
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Age-range was 19–57  years. The basic clinical charac-
teristics are summarized in Table  1. Significant medical 
history was noted in only four patients. One volunteer 
had a history of skin disease (psoriasis) that was not active 
for 3  years. One volunteer had well controlled DM type 
2 without clinical signs of diabetic neuropathy. Only one 
volunteer had more than one significant chronic disease 
with well controlled hypertension and hypothyroidism.
All four studied parameters (index 1, index 2, index 3 
and VAS) distributed normally among the whole cohort 
and among both genders. Age and gender were not asso-
ciated with these parameters in a multivariate analysis.
Fifteen minutes after histamine-SPT, there were sta-
tistically significant differences between arms in favor 
of EC over placebo in all four studied parameters of 
pruritus (Fig.  1). Index1 in EC 3.7 ±  2.3 versus 5 ±  3.5 
(p  =  0.007) in placebo, index 2 in EC 2.6  ±  2.1 versus 
3.8 ± 2.8 (p = 0.002) in placebo, index 3 of EC 6.3 ± 3.8 
versus 8.8 ± 5.8 (p = 0.03) and VAS in EC 3.7 ± 1.9 ver-
sus 4.4 ± 2.3 (p = 0.003).
For all the three different histamine concentrations, 
there were no significant differences between arms 
treated with EC or placebo in the indurations areas 
of the wheal and flare reactions, 15  min following the 
histamine-SPT (Fig.  2). In concentration 2.5  mg/ml in 
EC 4.3 + 0.9 versus 4.5 ± 0.8 mm2 in placebo (p = 0.1), 
in concentration 5.0  mg/ml in EC 4.9  ±  0.7 versus 
4.9 ± 0.6 mm2 in placebo (p = 0.8) and in concentration 
10 mg/ml in EC 5.04 ± 0.8 versus 5.0 ± 0.8 mm2 in pla-
cebo (p = 0.6).
No significant side effects were reported during the 
study.
Discussion
We found that applying topical EC spray, prior to his-
tamine-SPT, reduced significantly the symptoms of 
pruritus in comparison with placebo (topical saline). In 
addition, EC spray was free of adverse effects and did not 
reduce the wheal and flare reactions. Taken together, our 
results suggest that EC spray may be ideal for preven-
tion of pruritus secondary to allergy skin testing, with-
out masking the SPT results. Although tested here on 
adult volunteers, EC prevention may specifically ben-
efit children referred to SPT and indeed EC is safe and 
approved for the pediatric population [12, 13]. To the 
best of our knowledge, this is the first study that exam-
ined EC-spray as an antipruritic preventive measure 
Table 1 Clinical characteristics of 44 volunteers in study
Sex (m/f ) 19/25
Age
 Range (years) 19–57
 Mean ± SD (years) 32 ± 7.4
Ethnicity
 Caucasians 44 (100 %)
 Other 0 (0 %)
Medical History (number of individuals) Hypertension (1)
Hypothyroidism (2)
Non‑active psoriasis (1)






















Fig. 1 Effect on pruritus caused by histamine skin prick test with 
pretreatment of ethyl‑chloride (EC) or placebo. Fifteen minutes after 
histamine skin prick test, there were statistically significant differ‑




























Fig. 2 Effect of preventive treatment with ethyl‑chloride (EC) or 
placebo on the wheal and flare indurations area following histamine 
skin prick test. For all the three different histamine concentrations, 
there were no significant differences between arms treated with EC 
or placebo in the indurations areas of the wheal and flare reactions
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before SPT. We have previously shown, in a double-blind 
placebo-controlled prospective study, that EC spray is an 
effective antipruritic agent when given 15 min after his-
tamine SPT [7]. EC spray also did not change the wheal 
and flare reactions [7]. Waibel et  al. conducted a rand-
omized, double masked, placebo-controlled study on 18 
individuals to evaluate the effect of EC spray on pain, 
caused by SPT. SPT were performed within 5–10 s of EC 
spray application. The main findings were that EC spray 
did not reduce the histamine and aeroallergen wheal and 
flare indurations areas during SPT [1]. Pain was reduced 
in some patients yet without statistical significance in 
comparison with the placebo group [1]. Pain and pruritus 
sensations may have some similar biological components 
and both may be triggered by histamine, yet they differ 
in some biological and physiological aspects [14, 15]. It 
may well be that the different symptoms of pain and pru-
ritus respond differently to EC-spray [1, 7]. It is also pos-
sible, that the difference in sample size between the study 
of Waibel et al. and the current study, contributed to the 
significant reduction in pruritus described here.
Histamine is released from mast cells when they are 
activated under various inflammatory conditions [14, 
15]. Possible explanation for the pruritus induced by his-
tamine was proposed by Han et  al. who demonstrated 
that activation of histamine H1 receptor on C fibers by 
histamine may induce itching by activation of phospho-
lipase CB3 that links G protein-coupled receptors to an 
intracellular signaling network [16]. There are few possi-
ble mechanisms by which EC may alleviate pruritus: (1) 
direct local analgesic effect of EC on dedicated C fibers. 
These fibers can sense temperature changes and EC spray 
may inhibit pruritus by topical temporal freezing [17, 18]. 
(2) As suggested by the ‘gate theory’ of pain, central pro-
cessing of the pruritus mechanism, both itch and pain, 
can be reduced by soft rubbing, which activates fast-con-
ducting, low-threshold fibers [19]. It is therefore possible 
that pruritus reduction is based on a spinal antagonism 
between thermal and itch-processing neurons. The cold 
sensation caused by EC spray and stimulating the nerve 
does not allow the stimulus of pruritus sensation to be 
conducted. (3) Alleviating pruritus, even temporarily, 
may affect longer improvement of pruritus. In contrast 
to pain, removing the cause of pruritus does not neces-
sarily stop the itch and might even aggravate it (‘itch-
scratch-itch cycle’ theory) [20]. In the current study, EC 
was applied before the SPT and therefore it does not sup-
port this theory. (4) Local vasoconstriction by EC might 
contrast the vasodilatation caused by histamine, and in 
addition cooling inhibits activation of nociceptors. How-
ever, we believe that this possible antipruritic mechanism 
is the least likely explanation since there was no influence 
of EC on the wheal and flare induration area size.
Our study has limitations. It involves prevention of 
pruritus in histamine-SPT and not with other potential 
agents that cause pruritus. Therefore, one cannot draw 
conclusions about a general antipruritic effect of EC with 
other pruritogenic agents. Although participants in this 
study were blinded to the spray used, it is still possible 
that the transient cooling sensation of EC was recognized 
or at least suspected by the subjects. It may have influ-
enced the description of itching in the pruritus question-
naire and VAS. It is also important to notice that only 
adults were tested here and a study on the antipruritic 
effect of EC in children is needed.
Conclusion
Prevention and improvement of pruritus, caused by 
histamine-SPT, is feasible with topical EC spray with-
out masking the SPT results. It may be considered as an 
option to reduce pruritus discomfort of SPT.
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